Kidswell Bio

Kidswell Bio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Kidswell Bio (4584.T) as of Oct 18, 2026 is 268.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -4,400.49 % — a change of -106.10% (higher).

FCF Conversion

268.30 %

YoY

-106.10%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Kidswell Bio is 2026 268.30 % . FCF Conversion Rate (FCF/EBITDA) of Kidswell Bio was 2025 -4,400.49 % . It decreases by -106.10% higher compared to the previous year.

The Kidswell Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
100.59 JPY
Jan 1, 2020
0.04 JPY
Jan 1, 2021
126.89 JPY
Jan 1, 2022
212.34 JPY
Jan 1, 2023
432.37 JPY
Jan 1, 2024
63.80 JPY
Jan 1, 2025
-4,400.49 JPY
Jan 1, 2026
268.30 JPY
The Kidswell Bio FCF Conversion history
YEARFCF ConversionYoY
268.30 %-106.10%
-4,400.49 %-6,997.45%
63.80 %-85.24%
432.37 %+103.62%
212.34 %+67.35%
126.89 %+284,656.49%
0.04 %-99.96%
100.59 %+107.44%
48.49 %-66.25%
143.68 %+85.73%
77.36 %-36.90%
122.60 %-12.76%
140.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kidswell Bio Stock analysis

What does Kidswell Bio do? Kidswell Bio Corp, based in Chuo-Ku, Tokyo, operates in the Health Care sector with a focus on Biotechnology. The company develops biopharmaceutical products, including biosimilars for cancer, renal diseases, and eye conditions, as well as innovative therapies such as anti-RAMP2 antibodies and regenerative medicine using stem cells for pediatric heart diseases and congenital disorders. Listed on 30 November 2012, it employs 41 full-time staff. Kidswell Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kidswell Bio stock

FCF Conversion Rate (FCF/EBITDA) of Kidswell Bio is 268.30 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Kidswell Bio changed from -4,400.49 % to 268.30 %, representing a -106.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Kidswell Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Kidswell Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Kidswell Bio

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Kidswell Bio